COFCO Biochemicals, Star Lake Science and Technology, Xiamen Xiangyu 2017 Performance Forecast

Cofco Biochemicals forecast s2017 net profit growth of 65.25%-96.73% YoY
YHwJanuary 31, 2018, Cofco Biochemistry (Anhui) Co., Ltdissued the 2017 annual results forecast, announced that: the performance forecast period (earnings forecast period( January 1, 2017 - December 31, 2017) The Company realized net profit attributable to shareholders of listed companies of RMB210 million to RMB25,000, an increase of 65.25% to 96.73% over the same period last yearYHwStar Lake Technology is expected to lose 170 million yuan in 2017YHwJanuary 30, 2018, Guangdong Zhaoqing Xinghu Biotech Co., Ltdannounced the 2017 annual results of the forecast loss announcement, the announcement said: after preliminary estimates by the financial sector, The Company's net profit attributable to shareholders of listed companies in 2017 is expected to be loss-making compared with the same period last year (statutory disclosure data), and the net profit attributable to shareholders of listed companies will be approximately RMB170 million, and net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses will be about -164 millionYHw
The main reasons for the pre-loss of the current period:
the impact of YHw1, the main business operating lossesThe company's main business in 2017 suffered losses due to the increase in cost and other factors such as higher cost and higher raw material prices due to the impact of environmental protection, and the increase in impairment losses on various assets under the impairment test at the end of the yearYHw
2, the impact of non-recurring businessIn 2016, the Company made an investment income of RMB35.96 million from the sale of the equity of the subsidiary and RMB12.93 million for the disposal of property and land use rightsThere were no significant asset disposal transactions in 2017YHw
Lu anti-pharma forecast 2017 net profit increased by 336.83%-353.40% YoY
YHwon January 26, 2018, Shandong Lu Anti-Pharmaceutical Co., Ltdannounced the 2017 annual results advance announcement, The announcement said: "The net profit attributable to shareholders of listed companies in 2017 will increase by 85 million yuan to 90 million yuan, an increase of 292.10 percent to 309.28 percent, compared with the same period a year earlier(statutory disclosure data)." The company's non-recurring profit and loss attributable to the shareholders of listed companies in the current year is about 36 million yuan, of which the main collection of various types of government subsidies included in the current profit and loss in 2017Net profit attributable to shareholders of listed companies, net of non-recurring gains and losses, will increase by RMB61 million to RMB64 million, an increase of 336.83 percent to 353.40 percent, compared with the same period a year earlier (statutory disclosure data)YHw
Main reasons for the pre-growth (or pre-decrease) of current earnings:YHw1Main Business Impact During the reporting period, the prices of the company's main products increased steadily, the gross margin of the formulation varieties increased, and the year-on-year increase in operating profit was larger YHw
　　2 Since the fourth quarter of 2017, due to the market supply and demand constraints, the company's veterinary antibiotic tethromycin series of products prices have risen significantly YHw
　　3 Impact of non-operating profit and loss The non-recurring profit and loss for 2017 is expected to increase by about $36 million over the same period last year, mainly due to an increase in the amount of various types of government subsidies collected in 2017 that are included in the current profit and loss YHw Xiangyu expects 2017 net profit to decrease by 35%-48% YoY YHw On January 19, 2018 Xiamen Xiangyu Co., Ltd announced its 2017 annual results forecast, which said: Preliminary estimates by the financial department In 2017, the Company expects net profit attributable to shareholders of listed companies to be RMB66,098 million to RMB746.27 million, an increase of RMB234.54 million to RMB31.983 million, an increase of 55% to 75% YoY After deducting non-recurring gains and losses, the company's net profit attributable to shareholders of listed companies in 2017 is expected to be RMB340.12 million to RMB425.41 million, a decrease of 35% to 48% compared with the same period last year YHw
　　The main reasons for the pre-growth of the current period: YHw Company's pre-growth is mainly due to the rapid development of the main business: (1) 2017, the company continued to consolidate and strengthen the core product supply chain service system, through accelerating the construction of the logistics system to enhance comprehensive competitiveness, business scale increased significantly, the main business revenue increased by about 71% ;(2) In the main business operation, the company through hedging and foreign exchange transactions to reduce the risk of commodity price volatility and exchange rate wave risk, 2017 futures and foreign exchange contracts fair value variable profit and loss and disposal profit and loss increased significantly yo-yo; YHw
　　The Company expects the non-recurring profit and loss for 2017 to be approximately RMB320.86 million, mainly: (1) the fair value variable profit and disposal gains and losses of futures and foreign exchange contracts that are not applicable to hedge accounting, which are in match ingon sin-related with the main business; YHw Cofco Biochemicals forecast 2017 net profit growth of 65.25%-96.73% YoY
YHw January 31, 2018, Cofco Biochemistry (Anhui) Co., Ltd issued its 2017 annual results forecast, announced: earnings forecast: earnings forecast During the period (January 1, 2017 - December 31, 2017), the Company realized net profit attributable to shareholders of listed companies of RMB210 million to RMB25,000, an increase of 65.25% -96.73% over the same period last year YHw Star Lake Technology is expected to lose 170 million yuan in 2017 YHw January 30, 2018, Guangdong Zhaoqing Xinghu Biotech Co., Ltd announced the 2017 annual results of the forecast loss announcement, the announcement said: after preliminary estimates by the financial sector, The Company's net profit attributable to shareholders of listed companies in 2017 is expected to be loss-making compared with the same period last year (statutory disclosure data), and the net profit attributable to shareholders of listed companies will be approximately RMB170 million, and net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses will be about -164 million YHw
　　The main reasons for the pre-loss of the current period:
the impact of YHw 1, the main business operating losses The company's main business in 2017 suffered losses due to the increase in cost and other factors such as higher cost and higher raw material prices due to the impact of environmental protection, and the increase in impairment losses on various assets under the impairment test at the end of the year YHw
　　2, the impact of non-recurring business In 2016, the Company made an investment income of RMB35.96 million from the sale of the equity of the subsidiary and RMB12.93 million for the disposal of property and land use rights There were no significant asset disposal transactions in 2017 YHw
　　Lu anti-pharma forecast 2017 net profit increased by 336.83%-353.40% YoY
YHw on January 26, 2018, Shandong Lu Anti-Pharmaceutical Co., Ltd announced the 2017 annual results advance announcement, The announcement said: "The net profit attributable to shareholders of listed companies in 2017 will increase by 85 million yuan to 90 million yuan, an increase of 292.10 percent to 309.28 percent, compared with the same period a year earlier(statutory disclosure data)." The company's non-recurring profit and loss attributable to the shareholders of listed companies in the current year is about 36 million yuan, of which the main collection of various types of government subsidies included in the current profit and loss in 2017 Net profit attributable to shareholders of listed companies, net of non-recurring gains and losses, will increase by RMB61 million to RMB64 million, an increase of 336.83 percent to 353.40 percent, compared with the same period a year earlier (statutory disclosure data) YHw
　　Main reasons for the pre-growth (or pre-decrease) of current earnings: YHw 1 Main Business Impact During the reporting period, the prices of the company's main products increased steadily, the gross margin of the formulation varieties increased, and the year-on-year increase in operating profit was larger YHw
　　2 Since the fourth quarter of 2017, due to the market supply and demand constraints, the company's veterinary antibiotic tethromycin series of products prices have risen significantly YHw
　　3 Impact of non-operating profit and loss The non-recurring profit and loss for 2017 is expected to increase by about $36 million over the same period last year, mainly due to an increase in the amount of various types of government subsidies collected in 2017 that are included in the current profit and loss YHw Xiangyu expects 2017 net profit to decrease by 35%-48% YoY YHw On January 19, 2018 Xiamen Xiangyu Co., Ltd announced its 2017 annual results forecast, which said: Preliminary estimates by the financial department In 2017, the Company expects net profit attributable to shareholders of listed companies to be RMB66,098 million to RMB746.27 million, an increase of RMB234.54 million to RMB31.983 million, an increase of 55% to 75% YoY After deducting non-recurring gains and losses, the company's net profit attributable to shareholders of listed companies in 2017 is expected to be RMB340.12 million to RMB425.41 million, a decrease of 35% to 48% compared with the same period last year YHw
　　The main reasons for the pre-growth of the current period: YHw Company's pre-growth is mainly due to the rapid development of the main business: (1) 2017, the company continued to consolidate and strengthen the core product supply chain service system, through accelerating the construction of the logistics system to enhance comprehensive competitiveness, business scale increased significantly, the main business revenue increased by about 71% ;(2) In the main business operation, the company through hedging and foreign exchange transactions to reduce the risk of commodity price volatility and exchange rate wave risk, 2017 futures and foreign exchange contracts fair value variable profit and loss and disposal profit and loss increased significantly yo-yo; YHw
　　The Company expects the non-recurring profit and loss for 2017 to be approximately RMB320.86 million, mainly: (1) the fair value variable profit and disposal gains and losses of futures and foreign exchange contracts that are not applicable to hedge accounting, which are in match ingon sin-related with the main business; YHw